Cormorant reports 5.56% stake in Rapport Therapeutics
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of common stock of Rapport Therapeutics, Inc. in an amended Schedule 13G filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of common stock of Rapport Therapeutics, Inc. in an amended Schedule 13G filing. They report beneficial ownership of 2,657,521 shares of common stock, representing 5.56% of the class.
The reporting persons have shared voting and dispositive power over all 2,657,521 shares and no sole voting or dispositive power. The ownership percentage is based on 47,826,929 shares of common stock outstanding as of May 4, 2026, as stated in Rapport’s Form 10-Q for the quarter ended March 31, 2026.
Key Figures
Key Terms
beneficial owner regulatory
investment adviser financial
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Rapport Therapeutics (RAPP) does Cormorant Asset Management report owning?
What level of voting power does Cormorant Asset Management have in Rapport Therapeutics (RAPP)?
Who are the reporting persons in the Rapport Therapeutics (RAPP) Schedule 13G/A amendment?
Does Cormorant Asset Management claim to be the beneficial owner of all reported Rapport (RAPP) shares for all purposes?
AI-generated analysis. How Rhea-AI works. Not financial advice.